|
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IDH1 mutations are common in malignant gliomas in older children, suggesting that a subset of these lesions may be biologically similar to malignant gliomas arising in younger adults and may be associated with a more favorable prognosis.
|
20725730 |
2011 |
|
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Association Between IDH1 and IDH2 Mutations and Preoperative Seizures in Patients with Low-Grade Versus High-Grade Glioma: A Systematic Review and Meta-Analysis.
|
29288860 |
2018 |
|
Malignant Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Classification based on IDH1/2 mutation status and Ki-67 expression level could be more convenient for clinical application and guide personalized treatment in malignant gliomas.
|
26338964 |
2015 |
|
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CMRO<sub>2</sub> showed the highest diagnostic performance for IDH gene mutation detection in low-grade glioma (AUC, 0.818) and MTI in high-grade glioma (AUC, 0.854) and for all WHO grades (AUC, 0.899) among all biomarkers.
|
27982759 |
2017 |
|
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
En bloc resection revealed a high-grade glioma with sarcomatous components that was immunoreactive for the R132H variant of IDH1 by antibody.
|
27153165 |
2017 |
|
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
|
28122345 |
2017 |
|
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.
|
22869205 |
2012 |
|
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Integrated genomic characterization of IDH1-mutant glioma malignant progression.
|
26618343 |
2016 |
|
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Integrated genomic characterization of IDH1-mutant glioma malignant progression.
|
26618343 |
2016 |
|
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Isocitrate dehydrogenase 1 gene (IDH1) R132H mutation status was also recently identified as a prognostic factor for malignant gliomas.
|
24929863 |
2014 |
|
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
It is proposed that isocitrate dehydrogenase 1 (IDH1) mutation predicts the outcome in patients with high-grade glioma.
|
26316565 |
2015 |
|
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Most IDH-wildtype tumors showing histopathological and radiological features of low-grade diffuse astrocytoma exhibit molecular and clinical features of high-grade glioma and may represent an early stage of primary glioblastoma.
|
29444314 |
2018 |
|
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Mutational landscape and clonal architecture in grade II and III gliomas.
|
25848751 |
2015 |
|
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 are found frequently in malignant gliomas and are likely involved in early gliomagenesis.
|
22136423 |
2012 |
|
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutations of NADP(+)-dependent isocitrate dehydrogenases encoded by IDH1 and IDH2 occur in a majority of several types of malignant gliomas.
|
19228619 |
2009 |
|
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
|
19901110 |
2009 |
|
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Of 158 tumors with sufficient tissue, 110 (70 %) showed nuclear cMYC immunopositivity--most frequent (95 %, χ(2) p = 0.0248) and intense (mean 1.33, ANOVA p = 0.0179) in anaplastic astrocytomas versus glioblastomas (63 %) or low grade gliomas (74 %). cMYC expression associated with younger age as well as p53 immunopositivity (OR = 3.6, p = 0.0332) and mutant IDH1 (R132H) (OR = 7.4, p = 0.06) among malignant gliomas in our cohort.
|
23934175 |
2013 |
|
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Patient 2, with malignant glioma with primitive neuroectodermal tumor (MGPNET), had a secondary GBM with a noncanonical isocitrate dehydrogenase 1 (IDH1) mutation and 11-year-survival; autopsy showed encasement of the entire bilateral ventricular system by SVS.
|
26308254 |
2016 |
|
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patients with IDH1-WT show reduced NCF compared with those with IDH1-M malignant gliomas.
|
27576872 |
2016 |
|
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PET with <sup>18</sup>F-GE-180 and <sup>18</sup>F-FET provides differing imaging information in HGG dependent on the IDH-mutational status, with diverging spatial overlap and vast exceedance of contrast-enhancement in MRI.
|
30244386 |
2019 |
|
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Polar spongioblastoma: A high-grade glioma that does not contain the IDH1 mutation or 1p/19q LOH.
|
20102524 |
2010 |
|
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recent investigations of malignant gliomas have identified additional genetic and chromosomal abnormalities which cluster with IDH1 mutations into two distinct subgroups.
|
25471051 |
2015 |
|
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recently, mutations of the ATRX gene have been found in various subtypes and grades of gliomas and were shown to refine the prognosis of malignant gliomas in combination with IDH and 1p/19q status.
|
24559763 |
2014 |
|
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule.
|
25391653 |
2015 |
|
Malignant Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Similarly, in human malignant gliomas harbouring IDH1 mutations, we find markedly elevated levels of 2HG.
|
19935646 |
2009 |